Skip Nav Destination
Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Cancer Res (2018) 78 (13_Supplement): CT179.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
- Anne Catherine Bretz
- Ulrike Parnitzke
- Kerstin Kronthaler
- Tobias Dreker
- René Bartz
- Frank Hermann
- Astrid Ammendola
- Tanja Wulff
- Svetlana Hamm
Journal for ImmunoTherapy of Cancer (2019) 7 (1)